☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Incyte
Incyte and Syndax Receives US FDA Approval for Niktimvo (axatilimab-csfr) to Treat Chronic Graft-Versus-Host Disease (GvHD)
August 16, 2024
Incyte Reports Topline Data from P-III (inMIND) Trial of Monjuvi to Treat Relapsed or Refractory FL
August 16, 2024
Incyte to Acquire Escient Pharmaceuticals and its MRGPR Antagonist Assets
April 24, 2024
Incyte and China Medical System Sign a Collaboration & License Agreement for Povorcitinib Use in Autoimmune and Inflammatory Derma...
April 2, 2024
Incyte Highlights Results from the P-II Trial of Povorcitinib for the Treatment of Prurigo Nodularis at AAD’24
March 11, 2024
Incyte Reports the US FDA’s Acceptance of BLA for Axatilimab with Priority Review to Treat Chronic Graft-Versus-Host Disease (GVHD...
February 28, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.